In patients diagnosed with LAM, 83.52% was diagnosed by elevated VEGF-D levels, 12.52% was diagnosed by systemic clinical evaluation, and only 3.96% of the total patients underwent lung biopsy to achieve a definite diagnosis. This evidence concerns the gene VEGFD and lymphangioleiomyomatosis.